These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1569 related articles for article (PubMed ID: 32376414)

  • 21. Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis.
    Pulli B; Ali M; Iwamoto Y; Zeller MW; Schob S; Linnoila JJ; Chen JW
    Antioxid Redox Signal; 2015 Dec; 23(16):1255-69. PubMed ID: 26058518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non-alcoholic steatohepatitis (NASH).
    Hada N; Katsume A; Kenichi K; Endo C; Horiba N; Sudoh M
    Pharmacol Res Perspect; 2023 Jun; 11(3):e01094. PubMed ID: 37204099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
    Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
    Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of miR-188-5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway.
    Riaz F; Chen Q; Lu K; Osoro EK; Wu L; Feng L; Zhao R; Yang L; Zhou Y; He Y; Zhu L; Du X; Sadiq M; Yang X; Li D
    J Cell Mol Med; 2021 Apr; 25(8):4073-4087. PubMed ID: 33689215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hedgehog-YAP Signaling Pathway Regulates Glutaminolysis to Control Activation of Hepatic Stellate Cells.
    Du K; Hyun J; Premont RT; Choi SS; Michelotti GA; Swiderska-Syn M; Dalton GD; Thelen E; Rizi BS; Jung Y; Diehl AM
    Gastroenterology; 2018 Apr; 154(5):1465-1479.e13. PubMed ID: 29305935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
    Sivakumar P; Saul M; Robinson D; King LE; Amin NB
    Sci Rep; 2024 Jul; 14(1):17072. PubMed ID: 39048608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of the Role of Stellate Cell VCAM-1 in NASH Models in Mice.
    Chung KJ; Legaki AI; Papadopoulos G; Gercken B; Gebler J; Schwabe RF; Chavakis T; Chatzigeorgiou A
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.
    Bhattacharya D; Basta B; Mato JM; Craig A; Fernández-Ramos D; Lopitz-Otsoa F; Tsvirkun D; Hayardeny L; Chandar V; Schwartz RE; Villanueva A; Friedman SL
    JHEP Rep; 2021 Jun; 3(3):100237. PubMed ID: 34151243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
    J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction.
    Li S; Li X; Chen F; Liu M; Ning L; Yan Y; Zhang S; Huang S; Tu C
    J Nutr Biochem; 2022 Feb; 100():108888. PubMed ID: 34695558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diethyldithiocarbamate inhibits the activation of hepatic stellate cells via PPARα/FABP1 in mice with non-alcoholic steatohepatitis.
    Sun X; Yu Q; Kang B; Zhao X; Li H; Liu H; Liu L; Wang P; Cong M; Liu T
    Biochem Biophys Res Commun; 2023 Jan; 641():192-199. PubMed ID: 36535078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
    Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
    Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells.
    Kiagiadaki F; Kampa M; Voumvouraki A; Castanas E; Kouroumalis E; Notas G
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):891-899. PubMed ID: 29287776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 79.